Climb Bio Inc. (CLYM)
1.33
0.08 (6.40%)
At close: Mar 13, 2025, 1:43 PM
6.40% (1D)
| Bid | 1.34 |
| Market Cap | 89.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.7 |
| PE Ratio (ttm) | -0.78 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.42 |
| Volume | 196,211 |
| Avg. Volume (20D) | 445,748 |
| Open | 1.28 |
| Previous Close | 1.25 |
| Day's Range | 1.26 - 1.41 |
| 52-Week Range | 1.20 - 11.55 |
| Beta | -0.18 |
About CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, I...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 9
Stock Exchange NASDAQ
Ticker Symbol CLYM
Website https://eliemtx.com
4 months ago
+7.12%
Climb Bio shares are trading higher. The company a...
Unlock content with
Pro Subscription